Lai-ping Zhong

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

albumin paclitaxel, cispatin, tislelizumab · Oncology
Albumin paclitaxel is a targeted chemotherapy drug that delivers paclitaxel directly to tumors, while tislelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 pathway to enhance anti-tumor immune response, and cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Lai-ping Zhong portfolio CI brief
Lai-ping Zhong pipeline updates RSS

Frequently asked questions about Lai-ping Zhong

What is Lai-ping Zhong's pipeline?

Lai-ping Zhong has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include albumin paclitaxel, cispatin, tislelizumab.

Sector hub: All tracked pharma companies